Tactile Systems Technology, Inc.

Tactile Systems Technology, Inc.

TCMDNYSE / NASDAQHealthcareSmall cap

$25.60-$0.39 (-1.5%)

Last close · Data as of Nov 20, 2026

Market cap
$567.7M
P/E
29.7x
EV / EBITDA
12.4x
Revenue
$329.5M
Net margin
5.8%
ROCE
14.8%

+7.0% over the last year

Tactile Systems Technology, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+8.8%
3M
+9.3%
6M
+3.1%
1Y
+7.0%
5Y
+8.7%

52-week range

Day change -$0.39 (-1.5%) from $26 to $26 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TCMD, bought on each weekday since 2021.

News & filings

What Tactile Systems Technology filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 31.1 times interest costs.

Concerns (1)

  • Return on equity of 8.7%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.

Read moreShow less

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Sector
Healthcare
Shares outstanding
22.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$567.7M
P/E
29.7x
P/B
2.6x
EV / EBITDA
12.4x
EV / Sales
1.5x
P/S
1.7x
52-week high
$33.05
52-week low
$21.71

Profitability

Operating margin
8.9%
Net margin
5.8%
EBITDA margin
11.8%
ROE
8.7%
ROCE
14.8%
ROIC
13.9%
ROA
7.0%
Asset turnover
1.20

Growth

Revenue
$329.5M
Revenue growth, 1Y
12.5%
Revenue CAGR, 3Y
10.1%
Net profit growth, 1Y
12.5%
Free cash flow
$40.3M

Solvency

Current ratio
4.03
Debt / Equity
0.07
Debt / Assets
0.06
CFO / Net profit
2.24
Cash / Market cap
17.5%

Where the revenue went

Of every $100 of FY2025 revenue, $6 was left as net income.

Tactile Systems Technology, Inc. income statement flow, FY2025
Tactile Systems Technology, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$79.4M
RevenueGross profit$250.1M
Gross profitResearch and development$8.5M
Gross profitSelling, general and administrative$209.9M
Gross profitOther operating expenses$2.4M
Gross profitOperating income$29.3M
Operating incomePretax income$29.3M
Interest and other incomePretax income$2.1M
Pretax incomeTax and other$12.3M
Pretax incomeNet income$19.1M

Revenue and net profit

Revenue grew 12.5% in FY2025; net profit is the dashed line.

Tactile Systems Technology, Inc. revenue and net profit by fiscal year
Tactile Systems Technology, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$246.8M-$17.9M
FY2023$274.4M$28.5M
FY2024$293.0M$17.0M
FY2025$329.5M$19.1M

Cash flows

FY2025: $42.8M from operations, $40.3M free after investment (dashed).

Tactile Systems Technology, Inc. operating and free cash flow by fiscal year
Tactile Systems Technology, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$5.2M$3.3M
FY2023$35.9M$33.4M
FY2024$40.7M$38.1M
FY2025$42.8M$40.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$329.5M+12.5%1Y
EBITDA
$39.0M+20.6%1Y
Net profit
$19.1M+12.5%1Y
Cash from operations
$42.8M+5.3%1Y
Free cash flow
$40.3M+5.6%1Y
Revenue CAGR, 3Y
10.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$329.5M$39.0M$19.1M$40.3M8.7%+12.5%+12.5%

Monthly returns

Month-by-month returns of TCMD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$273.9M
Liabilities$55.0M
Equity$218.9M
Paid-in capital$163.9M
Retained earnings$54.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TCMD highlighted.

P/E against peers

TCMD trades at 29.7x earnings against a peer median of -6.4x.

  1. Tactile Systems Technology, Inc. (this company)29.7x

EV / Sales, for the companies without earnings

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Tactile Systems Technology, Inc.TCMDthis company$567.7M29.7x2.6x8.7%12.4x
Altimmune, Inc.ALT$567.9M-6.4x2.5x-39.2%-6.4x
MiMedx Group, Inc.MDXG$563.0M11.6x2.2x18.9%5.3x
Rigel Pharmaceuticals, Inc.RIGL$559.7M1.5x1.4x93.8%4.4x
Ironwood Pharmaceuticals, Inc.IRWD$559.7M23.3x-2.1x-9.2%9.0x
Cytek Biosciences, Inc.CTKB$559.2M-8.4x1.6x-19.5%-28.3x
Cerus CorporationCERS$559.0M—8.7x-24.3%—
NeuroPace, Inc.NPCE$556.4M-25.9x29.2x-112.8%-50.2x
Fulgent Genetics, Inc.FLGT$553.8M-9.2x0.5x-5.4%-11.2x
Peer median—-6.4x1.9x-14.3%-6.4x

Year-to-date ROI

TCMD since 1 January, against earlier years.

Historical volatility

TCMD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Tactile Systems Technology, Inc. operating margin by fiscal year
Tactile Systems Technology, Inc. operating margin by fiscal year
DateOperating margin
FY2022-5.2%
FY20236.6%
FY20247.6%
FY20258.9%
LineFY2025
Cost of revenueCost Of Revenue$79.4M
Gross profitGross Profit$250.2M
Operating expensesOperating Expense$220.9M
Research and developmentResearch And Development$8.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$2.4M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$2.4M
Amortization$2.4M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$2.4M
Rent expense supplementalRent Expense Supplemental$10.7M
Total expensesTotal Expenses$300.2M
Pretax incomePretax Income$31.3M

Learn while you research

Academy chapters picked for Tactile Systems Technology, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →